In his professional life as well as in the sphere of public service, Robert A. Ingram has been a distinguished leader of initiatives that advance medical care.
The former chairman of OSI Pharmaceuticals, Inc., maker of the cancer drug Tarceva® (erlotinib), Robert is a general partner in Hatteras Venture Partners, located in Research Triangle Park, North Carolina, which invests in promising innovations in medicine.
In 2001, when Robert was the CEO of GlaxoWellcome, he accepted the invitation of former President George H.W. Bush to form and chair the CEO Roundtable on Cancer, a nonprofit organization comprised of chief executives committed to fighting cancer. Appointed by President George W. Bush, Robert also serves on the National Cancer Advisory Board of the National Institutes of Health, and he is a member of the Working Group that is assessing the National Cancer Program.
As chair of the North Carolina GlaxoSmithKline Foundation, Robert spearheads support for programs that promote the sciences, health and education.
“Bob is a tireless advocate for cancer causes nationally and in his home state of North Carolina,” says Bruce A. Chabner, MD, director of clinical research at Mass General Cancer Center and chairman of the NIH National Cancer Advisory Board.
